Are IDH mutations good minimal residual disease (MRD) markers in acute myeloid leukemia (AML)?
ROR1 and its role in CLL and other cancers
Thomas J. Kipps
Topics in multiple myeloma discussed at ASCO 2016
Identifying predictive markers for CLL
How to address the issue of access to new drugs in multiple myeloma
Paul Richardson et al.